| Target Price | $147.90 |
| Price | $127.00 |
| Potential |
16.46%
register free of charge
|
| Number of Estimates | 30 |
|
30 Analysts have issued a price target Abbott Laboratories 2026 .
The average Abbott Laboratories target price is $147.90.
This is
16.46%
register free of charge
$170.10
33.94%
register free of charge
$123.37
2.86%
register free of charge
|
|
| A rating was issued by 36 analysts: 24 Analysts recommend Abbott Laboratories to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Abbott Laboratories stock has an average upside potential 2026 of
16.46%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 41.95 | 45.12 |
| 4.59% | 7.55% | |
| EBITDA Margin | 21.15% | 26.66% |
| 2.37% | 26.07% | |
| Net Margin | 31.95% | 20.06% |
| 123.90% | 37.21% |
33 Analysts have issued a sales forecast Abbott Laboratories 2025 . The average Abbott Laboratories sales estimate is
This results in the following potential growth metrics:
22 Analysts have issued an Abbott Laboratories EBITDA forecast 2025. The average Abbott Laboratories EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Abbott Laboratories Analysts have issued a net profit forecast 2025. The average Abbott Laboratories net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 7.67 | 5.20 |
| 134.56% | 32.20% | |
| P/E | 24.40 | |
| EV/Sales | 5.01 |
32 Analysts have issued a Abbott Laboratories forecast for earnings per share. The average Abbott Laboratories EPS is
This results in the following potential growth metrics and future valuations:
Abbott Laboratories...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Oct 15 2025 |
| Benchmark |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 15 2025 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Oct 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


